Sage Journals: Discover world-class research

Retricted access

Case report

First published 2025-10

Rechallenge of an alternative CDK 4/6 inhibitor after hepatotoxicity in the treatment of hormone-positive metastatic breast cancer

Kasey Jackson, Kiera Roubal, Christopher Rangel [...]

Journal of Oncology Pharmacy Practice

Retricted access

Research article

First published 2024-12

Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors

Tanju Kapagan, Nilufer Bulut, Gokmen Umut Erdem

Journal of Oncology Pharmacy Practice

Open access

Research article

First published 2026

Nephrotoxicity secondary to CDK 4/6 inhibitors in advanced breast cancer patients and its impact on survival

Tugay Avci, Ahmet Anil Altunbas, Mustafa Sahbazlar [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2022

Clinicopathological Features Related to the Efficacy of CDK4/6 Inhibitor-Based Treatments in Metastatic Breast Cancer

Ayana Shikanai, Yoshiya Horimoto, Yumiko Ishizuka [...]

Breast Cancer: Basic and Clinical Research

Open access

Research article

First published 2021

Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective

Anna Maria Buehler, Gabriela Castilho, Pierre-Alexandre Dionne [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2025

A single-centre retrospective evaluation of potential drug-drug interactions in breast cancer patients undergoing CDK 4/6 inhibitors chemotherapy

Prajakta Harish Patil, Mrunal Pradeep Desai, Gayathri Baburaj [...]

Journal of Oncology Pharmacy Practice

Open access

Case report

First published 2026

Safe use of ribociclib in a patient with HR+/HER2− metastatic breast cancer receiving chronic hemodialysis

Dilek Çağlayan, Melek Çağlayan

Journal of Oncology Pharmacy Practice

Retricted access

Review article

First published 2019-2

Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Advanced Breast Cancer

Keith A. Hecht, Christopher Selby

Annals of Pharmacotherapy

Retricted access

Case report

First published 2024-6

A case of biopsy proven acute tubular injury from cyclin dependent kinase 4/6 inhibitor

Meghan Gwinn, Kammi Henriksen, Marco Bonilla

Journal of Onco-Nephrology

Retricted access

Research article

First published 2023-9

Ribociclib-induced visual hallucination in a patient with metastatic breast cancer

Tanju Kapagan, Nilufer Bulut, Serhat Demirer [...]

Journal of Oncology Pharmacy Practice

Search results